Overview

A Bioequivalence Study of Losartan Potassium Tablets (Containing Losartan Potassium 100 mg) in Normal, Healthy, Adults Under Fasting Conditions

Status:
Completed

Trial end date:
2018-03-16

Target enrollment:

Participant gender:

Summary

To demonstrate bioequivalence of single dose test formulation of Losartan potassium tablets (containing Losartan potassium 100 mg) of Pharmtechnology LLC, Republic of Belarus with reference Cozaar® (containing Losartan potassium 100 mg) of "Merck Sharpe & Dohme B.V.", Haarlem, the Netherlands in normal, healthy, adult, human subjects under fasting conditions.To monitor adverse events and ensure the safety

Phase:

Phase 1

Details

Lead Sponsor:

Pharmtechnology LLC

Collaborator:

Reliance Life Sciences Private Limited

Treatments:

Losartan